![]() Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. Before deciding to trade foreign exchange or any other financial instrument or cryptocurrencies you should carefully consider your investment objectives, level of experience, and risk appetite. Cryptocurrencies are not suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading or investing in cryptocurrencies carries with its potential risks. Currency trading on margin involves high risk and is not suitable for all investors. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. Prior results do not guarantee a similar outcome.Risk Disclosure: Fusion Media will not accept any liability for loss or damage as a result of reliance on the information contained within this website including data, quotes, charts and buy/sell signals. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.įollow us for updates on LinkedIn:, on Twitter: or on Facebook. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. In 2019 alone the firm secured over $438 million for investors. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Many of these firms do not actually litigate securities class actions. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. On this news, Surmodics' share price fell $10.57, or 28%, to close at $26.77 per share on January 19, 2023. Concurrently, we will be evaluating options to reduce our use of cash given this development." Based on our discussion with the Agency, our team and external advisors will determine the appropriate path forward. Surmodics stated, "We are evaluating the issues raised in the FDA's letter and plan to meet with Agency representatives regarding its contents. Although the information identified by the Agency to put the PMA application in approvable form would require additional testing and analysis, the letter did not question the human clinical data submitted nor request any further human clinical data. The letter stated that certain information within two general categories-biocompatibility and labeling-must be added by an amendment to the company's PMA application to place it in approvable form. In the letter, the FDA indicated that the application is not currently approvable, while providing specific guidance as to a path forward. Food and Drug Administration related to its premarket approval (PMA) application for the SurVeil™ drug-coated balloon (DCB). WHAT IS THIS ABOUT: On January 19, 2023, Surmodics announced it had received a letter from the U.S. toll-free at 86 or email or for information on the class action. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. SO WHAT: If you purchased Surmodics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. SRDX resulting from allegations that Surmodics may have issued materially misleading business information to the investing public. NEW YORK, Ma(GLOBE NEWSWIRE) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Surmodics Inc.
0 Comments
Leave a Reply. |